Printer Friendly

LIDAK INITIATES PHASE II CLINICAL TRIAL FOR ORAL HERPES

 LA JOLLA, Calif., April 12 /PRNewswire/ -- LIDAK Pharmaceuticals (NASDAQ: LDAKA) announced today initiation of a third Phase II clinical trial of its antiviral compound LIDAKOL(TM). The double-blind, placebo- controlled clinical trial is designed to test the safety, tolerance and efficacy of LIDAKOL as a topical treatment for recurrent oral herpes infections (commonly known as cold sores and fever blisters).
 The trial is being conducted by the Dermatology Division of the University of California-San Diego School of Medicine under an Investigational New Drug Application filed with the U.S. Food and Drug Administration. The UCSD Medical Center's Institutional Review Board formally approved the study protocol on March 10, 1993.
 According to David H. Katz, M.D., LIDAK's president and chief executive officer, "Initiation of this oral herpes study in the U.S. is an important element in our overall strategy to aggressively pursue the clinical development of LIDAKOL for both oral and genital herpes. Both indications address substantial patient populations and there is currently only one FDA-approved drug for treatment of herpes," said Katz.
 Two other Phase II clinical trials investigating topical LIDAKOL were initiated in November 1992. One is being conducted in Europe by LIDAK's European licensing partner, Brocades Pharma, b.v., on patients with recurrent oral herpes. The second study is being conducted by LIDAK in the United States with patients suffering from recurrent genital herpes.
 LIDAK Pharmaceuticals is developing pharmaceutical products for the health care industry. LIDAK is currently focusing its efforts on the commercialization of LIDAKOL as a treatment for herpes and other indications. Also, the company is developing its Large Multivalent Immunogen (LMI) technology for potential new therapies against cancer and viral diseases. The company's longer-term projects include the development of proprietary technology for potential new therapeutic and diagnostic approaches to diabetes, cancer and AIDS.
 -0- 4/12/93
 /CONTACT: Michael H. Lorber, vice president and CFO of LIDAK, 619-558-0364; or Fern Lazar or Kate de Santis of Dewe Rogerson, 212-688-6840, for LIDAK/
 (LDAKA)


CO: LIDAK Pharmaceuticals ST: California IN: MTC SU:

GK-OS -- NY017 -- 4657 04/12/93 09:36 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 12, 1993
Words:346
Previous Article:IBM ACQUIRES CATAPULT, INC.
Next Article:ERC EXPERIENCES TECHNICAL DIFFICULTY WITH FUEL CELL TEST AFTER 250 HOURS OF OPERATION; SECOND TEST PLANNED FOR AUGUST
Topics:


Related Articles
NEW ANTI-VIRAL COMPOUND REPORTED BY LIDAK PHARMACEUTICALS
LIDAK PHARMACEUTICALS' LEAD DRUG CANDIDATE COMPLETES FIRST PHASE II CLINICAL TRIAL
LIDAK REPORTS ADDITIONAL PHASE II GENITAL HERPES STUDY RESULTS LIDAKOL REDUCED PAIN ASSOCIATED WITH EPISODES
LIDAK PHARMACEUTICALS ANNOUNCES EARLY COMPLETION OF PHASE 3 LIDAKOL CLINICAL TRIAL IN EUROPE AND COMPLETION OF PHASE 2 IN THE U.S.
LIDAK PHARMACEUTICALS INITIATES A THIRD PHASE 3 CLINICAL TRIAL OF LIDAKOL IN THE UNITED STATES FOR EARLY TREATMENT OF ORAL HERPES
LIDAK PHARMACEUTICALS RECEIVES FDA CLEARANCE TO PROCEED WITH CANCER THERAPY CLINICAL TRIALS
LIDAK PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM PHASE 3 EUROPEAN CLINICAL TRIAL
LIDAK RESPONDS TO QUESTIONS REGARDING POSITIVE PHASE 3 CLINICAL TRIAL ANNOUNCEMENT
LIDAK PHARMACEUTICALS COMPLETES PATIENT TREATMENTS IN THREE PHASE 3 LIDAKOL TRIALS IN U.S. AND CANADA
LIDAK ANNOUNCES RESULTS OF PHASE 3 U.S./CANADIAN STUDIES OF LIDAKOL(TM) IN TREATMENT OF ORAL HERPES

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters